Adalimumab Kit
Product Images NDC 72606-022

Product Visual Gallery

This gallery contains 64 technical images submitted to the FDA as part of the official labeling for Adalimumab (NDC 72606-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celltrion Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Adalimumab Aaty 01)

Graph showing percent ACR20 responders over time (weeks) comparing two groups: one receiving 40 mg every other week and one receiving placebo. The response percentage increases sharply for the 40 mg group and stabilizes around 55-60%, while the placebo group plateaus around 20-30%.*

FDA Label Image

Figure 2 (Adalimumab Aaty 02)

A line graph showing the percentage of ASAS 20 response over 26 weeks comparing Adalimumab (N=208) with placebo (N=107). The vertical axis represents percentage response, ranging from 0 to 70%, while the horizontal axis shows time in weeks from 0 to 26. The Adalimumab group shows a rapid increase to about 60% response by week 8, maintaining around 50-60% through week 26. The placebo group has a much lower response, peaking below 30% around week 8 and declining afterward.*

FDA Label Image

Figure A (Adalimumab Aaty 03)

An instructional diagram showing two syringe device states labeled 'Before Use' and 'After Use' for an Adalimumab kit. It labels components including the cap, needle cover (with needle inside), window, stopper, plunger rod, body, and medicine within the device to illustrate proper parts before and after administering the injection.*

FDA Label Image

Figure B (Adalimumab Aaty 04)

An illustration showing a pre-filled syringe with a magnified inset highlighting the location for the expiration date, which is formatted as month and year. The syringe appears to be part of a kit for the human prescription drug Adalimumab by CELLTRION USA, Inc.*

FDA Label Image

Figure C (Adalimumab Aaty 05)

An instructional illustration showing a kit component of Adalimumab. The image highlights a long, slender device or vial with a magnified view of a rectangular window or indicator on the device, suggesting a detail relevant to usage or inspection.*

FDA Label Image

Figure D (Adalimumab Aaty 06)

An instructional illustration showing a pen-style injector device and a clock indicating a wait time of 15 to 30 minutes. The image likely relates to the preparation or use timing for the Adalimumab kit by CELLTRION USA, Inc.*

FDA Label Image

Figure E (Adalimumab Aaty 07)

An instructional diagram illustrating recommended self-injection and caregiver injection sites for Adalimumab. The areas marked in dark blue include the abdomen (around the navel) and the front thighs. The diagram shows these injection locations on a front view of a human body.*

FDA Label Image

Figure F (Adalimumab Aaty 08)

An illustration showing hands being washed under running water from a faucet. The image emphasizes hand hygiene with water flowing onto the hands over a sink basin.*

FDA Label Image

Figure G (Adalimumab Aaty 09)

An instructional illustration showing a person cleaning their skin, specifically the thigh area, with a wipe. The text 'clean your skin' is displayed above the image, indicating preparation steps before administering a medication or injection.*

FDA Label Image

Figure H (Adalimumab Aaty 10)

An instructional diagram illustrating the removal and disposal of the needle cover from a pen injector device. The image shows a hand pulling the needle cover upwards away from the pen, with a labeled arrow indicating the direction. An inset circle illustrates the proper disposal of the removed needle cover into a sharps container."*

FDA Label Image

Figure I (Adalimumab Aaty 11)

An instructional illustration showing two methods to hold an injection device at a 90-degree angle to the skin, either vertically or horizontally, likely demonstrating the proper technique for subcutaneous injection administration.*

FDA Label Image

Figure J (Adalimumab Aaty 12)

An instructional diagram for administering an injection using the Adalimumab kit. It shows a hand holding the injector device pressing it against the skin, with captions indicating stages: 'Start of Injection' with the first click, 'Injection is ongoing' with the second click and a 10-second timer, and 'End of Injection' with a 5-second countdown while the device remains pressed to the skin.*

FDA Label Image

Figure K (Adalimumab Aaty 13)

An instructional illustration showing a hand holding a device labeled Adalimumab above a patient's thigh, indicating upward removal. A magnified inset highlights a detail on the device, possibly a window or indicator. The image likely demonstrates part of the administration or removal process for the Adalimumab kit.*

FDA Label Image

Figure L (Adalimumab Aaty 14)

An instructional illustration showing the bottom part of an injection device with the needle cover highlighted and labeled. The image focuses on the needle cover area of the device likely included in the Adalimumab kit by CELLTRION USA, Inc.*

FDA Label Image

Figure M (Adalimumab Aaty 15)

An illustration showing a hand holding a test strip with a visible dark line, about to be inserted into a rectangular container with a hinged lid, depicting part of a testing or diagnostic kit procedure.*

FDA Label Image

Figure A (Adalimumab Aaty 16)

An instructional diagram illustrating components of an adalimumab prefilled syringe kit from CELLTRION USA, Inc. The labeled parts include the plunger, finger flange, viewing window, needle guard body, needle, and cap. Two views show the syringe before use with the needle covered by a cap, and after use with the needle exposed.*

FDA Label Image

Figure B (Adalimumab Aaty 17)

An instructional illustration depicting a syringe-like device with a zoomed-in view highlighting the location of the expiration date, formatted as month and year. The device is part of a kit for Adalimumab by CELLTRION USA, Inc.*

FDA Label Image

Figure C (Adalimumab Aaty 18)

An instructional diagram showing a close-up view of a medical device component, likely a syringe or injector tip used in the Adalimumab kit by CELLTRION USA, Inc. The magnified inset highlights the detailed tip structure, emphasizing proper alignment or insertion features.*

FDA Label Image

Figure D (Adalimumab Aaty 19)

Illustration showing a clock with shaded area indicating 15 to 30 minutes, next to an image of a syringe-like device with a green and blue plunger. The image suggests a waiting or preparation time related to the device.*

FDA Label Image

Figure E (Adalimumab Aaty 20)

An illustration showing recommended self-injection and caregiver injection sites for Adalimumab. The highlighted areas include the abdomen and front thighs on a human figure, indicating locations suitable for administering the medication.*

FDA Label Image

Figure F (Adalimumab Aaty 21)

An illustration showing a person washing hands under running water from a faucet. Two hands are held together beneath the stream of water above a sink basin, depicting hand hygiene.*

FDA Label Image

Figure G (Adalimumab Aaty 22)

An instructional illustration showing a person seated, wiping their thigh with a cloth or wipe. The text "clean your skin" appears, indicating a step for preparing the skin, likely for an injection or medical procedure.*

FDA Label Image

Figure H (Adalimumab Aaty 23)

Instructional diagram showing hand actions for using the Adalimumab kit by CELLTRION USA, Inc. It depicts removing a cap from a syringe with bidirectional arrows and an inset showing disposal of used components in a container.*

FDA Label Image

Figure I (Adalimumab Aaty 24)

Instructional illustration showing two techniques for injecting Adalimumab kit at a 45-degree angle. One image depicts injection into the upper arm, and the other into the thigh or abdomen area, with hand placement and injection angle highlighted.*

FDA Label Image

Figure J (Adalimumab Aaty 25)

An instructional illustration showing a hand administering an injection with a syringe. The syringe is positioned against the skin, with a black arrow pointing to the area of injection, indicating the proper injection technique for the Adalimumab kit by CELLTRION USA, Inc.*

FDA Label Image

Figure K (Adalimumab Aaty 26)

Illustration showing a hand holding a syringe with a teal-colored flange, positioned near a bent knee. An arrow points upward, indicating the direction for injection or syringe removal.*

FDA Label Image

Figure L (Adalimumab Aaty 27)

An instructional illustration showing a hand placing a syringe with a black plunger and green thumb rest into a disposal container, demonstrating safe syringe disposal.*

FDA Label Image

Figure A (Adalimumab Aaty 28)

An instructional illustration showing a syringe before and after use, with labeled parts including plunger, finger flange, body, medicine, needle, and cap, demonstrating the position of the medicine and needle cap removal relevant to the Adalimumab kit.*

FDA Label Image

Figure B (Adalimumab Aaty 29)

An illustration of a syringe with a focus inset showing the location of the expiration date labeled as 'EXP.: MONTH YEAR' on the syringe. The image highlights where to find the expiration date on the product.*

FDA Label Image

Figure C (Adalimumab Aaty 30)

An instructional illustration showing a syringe with a close-up magnification of the tip portion. The diagram highlights a specific feature or detail at the end of the syringe barrel, emphasizing the area for clarity in use or assembly.*

FDA Label Image

Figure D (Adalimumab Aaty 31)

An instructional illustration showing a clock indicating 15 to 30 minutes and an injection pen device. This image suggests a time frame related to the use or administration of the injection pen, likely part of a kit for adalimumab, but contains no branding or dosage information.*

FDA Label Image

Figure E (Adalimumab Aaty 32)

Illustration showing recommended self-injection and caregiver injection sites for Adalimumab. The diagram highlights areas on the abdomen around the navel and the front upper thighs in blue as the preferred injection locations for patients and caregivers administering the medication.*

FDA Label Image

Figure F (Adalimumab Aaty 33)

An instructional illustration showing hands being washed under running water from a faucet over a sink. The image emphasizes handwashing technique, likely related to hygiene or preparation procedures.*

FDA Label Image

Figure G (Adalimumab Aaty 34)

An instructional illustration showing a person cleaning their skin on the thigh area using a wipe. Text reads 'clean your skin,' indicating preparation for a skin procedure, likely an injection site for the Adalimumab kit.*

FDA Label Image

Figure H (Adalimumab Aaty 35)

An instructional illustration showing the proper removal of a needle cover from a syringe or pen injector, with an inset demonstrating disposal of the cover into a sharps container. The hands depict careful pulling of the cover straight off the needle, emphasizing safe handling and disposal.*

FDA Label Image

Figure I (Adalimumab Aaty 36)

This instructional illustration shows two methods for injecting Adalimumab using a syringe at a 45-degree angle. The top panel depicts an injection into the underside of the forearm, while the bottom panel shows an injection into the thigh.*

FDA Label Image

Figure J (Adalimumab Aaty 37)

An instructional illustration showing a hand holding a syringe to inject medication into a patient's arm. A black arrow points downward indicating the injection direction into the skin. This image demonstrates the proper technique for subcutaneous injection using a syringe included in a medication kit.*

FDA Label Image

Figure K (Adalimumab Aaty 38)

An instructional diagram showing a hand holding a syringe with a green and blue plunger, inserting the needle into a person's arm. A black arrow points toward the insertion site indicating the injection direction.*

FDA Label Image

Figure L (Adalimumab Aaty 39)

An illustration showing a hand holding a syringe with a needle poised above a sharps disposal container. The image depicts safe disposal of the syringe into the container, likely as part of instructions for the use of Adalimumab kit by Celltrion USA, Inc.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Auto-injector Label)

Label of Adalimumab kit containing adalimumab-aaty for injection, showing a strength of 40 mg/0.4 mL for subcutaneous use. The label includes details such as route of administration and appears to be from CELLTRION USA, Inc. The label layout includes dosage, barcode, and storage instructions.*

FDA Label Image

40 mg/0.4 mL Auto-injector Carton 1pk (Adalimumab Aaty 41)

Packaging label for Adalimumab-aaty injection, 40 mg/0.4 mL, single-dose auto-injector kit. The label includes usage instructions, storage conditions (store at 36°F to 46°F, protect from light), and manufacturer information for CELLTRION USA, Inc. The carton is folded flat and shows the product name, strength, dosage form, recommended dosage, barcode, and regulatory details.*

FDA Label Image

40 mg/0.4 mL Auto-injector Carton 2pk (Adalimumab Aaty 42)

Packaging label for Adalimumab kit containing adalimumab-aaty 40 mg/0.4 mL injection. The label indicates the kit includes 2 single-dose auto-injectors. Labeler information is CELLTRION USA, Inc. The packaging includes dosage instructions and storage information for this prescription drug.*

FDA Label Image

40 mg/0.4 mL Auto-injector Carton 4pk (Adalimumab Aaty 43)

Flat packaging label for Adalimumab-aaty injection, 40 mg/0.4 mL single-dose auto-injectors. The kit contains 4 auto-injectors and is labeled for subcutaneous use only. The label includes manufacturer information for CELLTRION USA, Inc., storage instructions, dosing record spaces, and a barcode.*

FDA Label Image

40 mg/0.4 mL Auto-injector Carton 6pk (Adalimumab Aaty 44)

Packaging label for Adalimumab-aday injection 40 mg/0.4 mL kit by CELLTRION USA, Inc. The label indicates it contains 6 single-dose auto-injectors and includes storage instructions and dosage recording space. The box design features product and labeler identification, with dosing and handling details.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe with safety guard Label)

The image shows a small label for Adalimumab-aaty, a human prescription drug kit by CELLTRION USA, Inc. The label includes strength information of 40 mg per 0.4 mL, along with a barcode and lot/expiration data area, on a pale yellow background.*

FDA Label Image

40 mg/0.4 mL Syringe Carton (with Guard 1PK)

Flat layout of the packaging label for Adalimumab-aaty Injection Kit by CELLTRION USA, Inc. The label indicates a 40 mg/0.4 mL single-dose prefilled syringe with safety guard. It includes administration instructions, storage recommendations, dosage information, and syringe usage guidance. The label features the NDC 71506-022-05 and barcode, and specifies that the product is for subcutaneous use only.*

FDA Label Image

40 mg/0.4 mL Syringe Carton (with Guard 2PK)

The image shows the packaging label for Adalimumab-aaty Injection Kit by CELLTRION USA, Inc. The label specifies a 40 mg/0.4 mL dosage, intended for subcutaneous use only. The box includes instructions with an illustration of a syringe with a safety guard. Additional details on storage and dosage recording space are also visible.*

FDA Label Image

40 mg/0.4 mL Syringe Carton (with Guard 4PK)

Flat packaging label for Adalimumab-aaty Injection KIT by CELLTRION USA, Inc. The label indicates a dosage strength of 40 mg/0.4 mL, featuring four single-dose prefilled syringes with safety guards. Instructions for storage and dosage recording are included, along with a barcode and NDC number 72606-022-07.*

FDA Label Image

40 mg/0.4 mL Syringe Carton (with Guard 6PK)

Flat packaging label for Adalimumab injection kit, showing a 40 mg/0.4 mL dose. The label includes instructions for single-dose prefilled syringes with safety guards and is labeled for dispensing by prescription only. The product is distributed by CELLTRION USA, Inc., and the design features text areas for syringe usage records and dosage recommendations.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Label)

Label for Adalimumab injection, 40 mg/0.4 mL, supplied as a kit. Label includes lot number and expiration date fields, a barcode, and the manufacturer’s name, CELLTRION USA, Inc. The label is primarily white with text in black and a blue box highlighting the dosage strength.*

FDA Label Image

40 mg/0.4 mL Syringe Carton 1pk (Adalimumab Aaty 51)

Carton packaging label for Adalimumab adalimumab-aaty kit by CELLTRION USA, Inc. The label indicates a single-dose prefilled syringe with a dosage of 40 mg/0.4 mL injection. Includes handling instructions, product and manufacturer details, barcode, and areas to record syringe removal dates from refrigeration.*

FDA Label Image

40 mg/0.4 mL Syringe Carton 2pk (Adalimumab Aaty 52)

The image shows a flat, unfolded packaging label for Adalimumab-aaty injection, 40 mg/0.4 mL, presented as a kit. It includes two single-dose prefilled syringes. The label highlights that the product is for subcutaneous use only and is labeled by CELLTRION USA, Inc. Storage instructions and dosage information are also displayed.*

FDA Label Image

40 mg/0.4 mL Syringe Carton 4pk (Adalimumab Aaty 53)

Flat carton packaging label for Adalimumab-aaty Injection, a kit containing 4 single-dose prefilled syringes of 40 mg/0.4 mL each. The label shows the product name, strength, dosage form, and usage instructions stating it is for subcutaneous use only. The labeler is CELLTRION USA, Inc. Storage recommendations and dosage recording space are also printed on the label.*

FDA Label Image

I40 mg/0.4 mL Syringe Carton 6pk (Adalimumab Aaty 54)

Flat layout of a packaging label for Adalimumab-aaty Injection 40 mg/0.4 mL kit by CELLTRION USA, Inc., showing images of single-dose prefilled syringes. The label includes dosing instructions, storage recommendations, a barcode, and mentions it is for subcutaneous use only with a prescription.*

FDA Label Image

Principal Display Panel (80 mg/0.8 mL Auto-injector Label)

Adalimumab 80 mg/0.8 mL injection kit label for subcutaneous use, labeled as adalimumab-aaty. The label includes dosage information and is marked for refrigerated storage. The product is manufactured by CELLTRION USA, Inc., with NDC 73063-0600-03.*

FDA Label Image

80 mg/0.8 mL Auto-injector Carton 1pk (Adalimumab Aaty 56)

Packaging label for Adalimumab-aaty Injection Kit by Celltrion USA, Inc. The label indicates a single-dose auto-injector containing 80 mg/0.8 mL of adalimumab-aaty. The label includes dosage instructions, storage conditions, a barcode, and spaces for recording injection dates.*

FDA Label Image

80 mg/0.8 mL Auto-injector Carton 2pk (Adalimumab Aaty 57)

Flat packaging label for Adalimumab injection, 80 mg/0.8 mL single-dose autoinjectors. This kit includes 2 autoinjectors and is labeled for human prescription use. The label shows storage instructions, recommended dosage information, a barcode, and is marked for distribution by Celltrion USA, Inc.*

FDA Label Image

Principal Display Panel (80 mg/0.8 mL Syringe with safety guard Label)

Adalimumab kit label showing the generic name adalimumab-aaty, with dosage strength marked as 40 mg/0.8 mL. The label includes manufacturer information for CELLTRION USA, Inc., and displays areas for lot number and expiration date at the bottom.*

FDA Label Image

80 mg/0.8 mL Syringe Carton (with Guard 1PK)

Packaging label for Adalimumab 80 mg/0.8 mL injection kit by CELLTRION USA, Inc. The label includes usage instructions, dosage information, barcode, and safety warnings. The kit contains a single-dose prefilled syringe with safety guard and is intended for prescription use only.*

FDA Label Image

80 mg/0.8 mL Syringe Carton (with Guard 1PK)

Packaging label for Adalimumab injection kit containing adalimumab-aaty with strength 80 mg/0.8 mL. The label specifies single-dose prefilled syringes with safety guard, includes dosage information and administration instructions. The labeler is Celltrion USA, Inc. Various usage and storage instructions are partially visible on the unfolded carton template.*

FDA Label Image

Principal Display Panel (80 mg/0.8 mL Syringe Label)

Adalimumab kit label from CELLTRION USA, Inc. Showing the proprietary name Adalimumab and the generic name adalimumab-aaty. The label includes a red box highlighting the dosage strength of 40 mg/0.4 mL. Lot number and expiration date fields are also visible but not filled in.*

FDA Label Image

80 mg/0.8 mL Syringe Carton 1pk (Adalimumab Aaty 62)

Adalimumab 80 mg/0.8 mL single-dose prefilled syringe kit packaging label from CELLTRION USA, Inc. The label includes product name, dosage strength, and dosage form as a prefilled syringe. Instructions for use and storage information are printed on the packaging.*

FDA Label Image

Principal Display Panel (20 mg/0.2 mL Syringe Label)

Label for Adalimumab-adty kit by CELLTRION USA, Inc. The label includes the proprietary name Adalimumab-adty, the strength 40 mg/0.4 mL, dosage form indication as a kit, and a space for lot number and expiration date. The label also contains barcode information.*

FDA Label Image

20 mg/0.2 mL Syringe Carton 2pk (Adalimumab Aaty 64)

Box packaging label for Adalimumab-aaty injection kit containing two single-dose prefilled syringes. Each syringe delivers 20 mg/0.2 mL of adalimumab-aaty. The label also includes product handling instructions, dosage recommendations, and is labeled for human prescription use by CELLTRION USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.